Science News
from research organizations

A future strategy for the treatment of patients with ulcerative colitis

Date:
June 24, 2010
Source:
World Journal of Gastroenterology
Summary:
A research team from China focused on the effects of the chemokine stromal cell-derived factor-1 receptor (CXCR4) antagonist AMD3100 on the intestinal epithelial barrier. They found that CXCR4 antagonist AMD3100 exerts therapeutic effects on experimental colitis by inhibiting colonic inflammation and enhancing epithelial barrier integrity.
Share:
       
FULL STORY

Ulcerative colitis (UC) is characterized by frequent diarrheal attacks and anal bleeding. Histologic characteristics of UC are the invasion of the crypt epithelium and lamina propria by peripheral blood mononuclear cells (PBMCs), disruption of the epithelial lining, and consequently mucosal ulceration and crypt abscess formation in the bowel wall.

Regulation of the migration of inflammatory leukocytes into the intestinal tissues is considered to be a therapeutic option for patients with UC. Chemokine stromal cell-derived factor-1 receptor (CXCR4) is specific receptor for chemokine chemokine stromal cell-derived factor-1 (CXCL12), and the latter is a potent chemoattractant for PBMCs. The expression of CXCL12 and CXCR4 on intestinal epithelial cells, lamina propria T cells and PBMCs are significantly increased in UC patients, and block of CXCR4 ameliorates the colonic inflammation in experimental colitis. Whether a CXCR4 antagonist enhances epithelial barrier function, however, has not been unequivocally addressed.

A research article to be published on June 21, 2010 in the World Journal of Gastroenterology addresses this question. This is the first study to report that, in addition to inflammation inhibition, the CXCR4 antagonist, AMD3100, also decreased epithelial apoptosis and gut permeability in experimental colitis, and consequently enhanced the epithelial barrier function.

Their results suggested a pivotal role of the CXCL12/CXCR4 chemokine axis in the pathogenesis of UC. By understanding the role of CXCR4 in colonic inflammation and epithelial barrier, this study may represent a future strategy for therapeutic intervention in the treatment of patients with UC.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Xia XM, Wang FY, Xu WA, Wang ZK, Liu J, Lu YK, Jin XX, Lu H, Shen YZ. CXCR4 antagonist AMD3100 attenuates colonic damage in mice with experimental colitis. World Journal of Gastroenterology, 2010; 16 (23): 2873 DOI: 10.3748/wjg.v16.i23.2873

Cite This Page:

World Journal of Gastroenterology. "A future strategy for the treatment of patients with ulcerative colitis." ScienceDaily. ScienceDaily, 24 June 2010. <www.sciencedaily.com/releases/2010/06/100624104532.htm>.
World Journal of Gastroenterology. (2010, June 24). A future strategy for the treatment of patients with ulcerative colitis. ScienceDaily. Retrieved May 30, 2015 from www.sciencedaily.com/releases/2010/06/100624104532.htm
World Journal of Gastroenterology. "A future strategy for the treatment of patients with ulcerative colitis." ScienceDaily. www.sciencedaily.com/releases/2010/06/100624104532.htm (accessed May 30, 2015).

Share This Page: